Answers are grounded in this paper and cite their sources.
The efficacy of temozolomide for glioblastoma multiforme is mainly influenced by MGMT promoter methylation, with additional modulation by TERT mutations. Evidence for other markers like ABCB1 polymorphisms and xCT/SLC7A11 expression is less established and warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Tripdatabase (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: